CD8A and cancer: An ideal immunotherapeutic cancer vaccine should comprise both TACA derived carbohydrate B-cell epitope and tumor associated antigen (TAA) -derived CD8+ T-cell epitopes to boost the sub-optimal antitumor B- and T cell immune responses often detected in cancer patients [8], [9], [10], [11].